In July last year, Australia became the first country to legalise ecstasy (MDMA) and magic mushrooms (psilocybin) for mental health disorders, including PTSD and depression. A bold move, it spurred medical businesses into action, seeking the proper approvals and getting the early advantage. At the same time, not all medical professionals were so thrilled, citing
Read More
In a bid to crack down on excessive vaping among the Aussie youth, the Australian government decided to nip the problem in the bud. From January 1, 2024, the Therapeutic Goods Administration (TGA) declared that disposable vapes can’t be imported to Australia, regardless of nicotine or therapeutic claims. Plus, come March 1, 2024, importing all
Read More
Bringing pharmaceutical weed to telehealth, medical cannabis company Vitura Health (ASX: VIT) has decided to acquire telehealth company Doctors on Demand for an aggregate consideration of $25 million. This deal includes an upfront cash payment, a deferred cash component, and an equity stake. The acquisition marks Vitura’s leap into new healthcare verticals, including urgent care,
Read More
Once again, medical cannabis producer Vitura Health (ASX: VIT) has become the only ASX-listed company operating in the medicinal cannabis space to both generate a profit and declare a dividend since its ASX initiation in 2019. The Company will pay a dividend to shareholders in respect of FY23. The Dividend, which will be paid at
Read More
Leading cannabis company providing a safe and reliable source of cannabis treatment products, Vitura Health (ASX: VIT) has released its financial results for the first half of FY2023, revealing a significant step up across the board following their recent business overhaul finalised earlier this year. You may not recognise the Company or its name just
Read More